KIN

Kindred Biosciences Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

KIN price

Kindred Biosciences

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment KIN

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

0.00%

1 year

0.00%

2 years

0.00%

5 years

0.00%

10 years

0.00%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals KIN

Valuation

P/E

Sector -4.26

Industry -4.26

P/BV

Sector 2.11

Industry 2.11

P/Revenue (PSR)

Sector 2.08

Industry 2.08

EV/EBITDA

Sector -546.19

Industry -546.19

EV/EBIT

Sector -37.31

Industry -37.31

P/EBITDA

0.00

Sector -50.76

Industry -50.76

P/EBIT

0.00

Sector -39.62

Industry -39.62

P/Total Assets

0.00

Sector 1.25

Industry 1.25

P/Net Current Assets

Sector -5.47

Industry -5.47

P/Working Capital

Sector -1.10

Industry -1.10

EPS

-0.93

Sector -1.94

Industry -1.94

BVPS

1.76

Sector 1.89

Industry 1.89

Efficiency

Gross Margin

0.00%

Sector 38.90%

Industry 38.90%

EBITDA Margin

-241.56%

Sector -13,872.56%

Industry -13,872.56%

EBIT Margin

-275.88%

Sector -4,253,834.43%

Industry -4,253,834.43%

Operating Margin

0.00%

Sector -36.74%

Industry -36.74%

Net Profit Margins

0.00%

Sector -37.51%

Industry -37.51%

Asset Turnover

0.03

Sector 0.03

Industry 0.03

Profitability

ROE

Sector -61.50%

Industry -61.50%

ROA

Sector -63.85%

Industry -63.85%

ROIC

Sector -498.30%

Industry -498.30%

Dividends

Dividend yield

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

Sector 2.89

Industry 2.89

Net Debt / EBITDA

6.89

Sector -39,048,222.71

Industry -39,048,222.71

Net Debt / EBIT

6.03

Sector -10.24

Industry -10.24

Net Debt / Equity

-0.74

Sector -0.60

Industry -0.60

Gross Debt / Equity

0.19

Sector -0.83

Industry -0.83

Equity/Assets

0.73

Sector 0.43

Industry 0.43

Liabilities/Assets

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

5.97%

Sector -

Industry -

5Y Earnings CAGR

17.33%

Sector -

Industry -

Fundamentals KIN

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
KIN Kindred Biosciences Inc.	$0.00	-	0.00%	0.00	0.00	0.00%	0.00%
JNJ Johnson & Johnson	$266.50	55.29%	1.93%	31.09	7.70	24.76%	21.48%
PFE Pfizer Inc.	$27.87	21.03%	6.26%	35.86	1.83	5.11%	6.86%
ABBV AbbVie Inc.	$256.91	27.42%	2.58%	74.16	-78.93	-106.44%	9.81%
NVO Novo Nordisk A/S	$45.62	-14.65%	3.95%	11.47	6.09	53.11%	35.32%
MRK Merck & Co. Inc.	$147.77	82.61%	2.24%	116.78	8.81	7.55%	4.76%
AZN AstraZeneca PLC	$161.98	3.71%	1.93%	24.59	5.10	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$66.29	45.78%	3.73%	14.81	6.16	41.55%	18.85%
ZTS Zoetis Inc.	$76.84	-49.43%	2.67%	12.20	10.25	84.02%	27.77%
REGN Regeneron Pharmaceuticals Inc.	$792.43	37.47%	0.44%	19.71	2.69	13.65%	27.86%
AMGN Amgen Inc.	$432.42	55.55%	2.22%	27.25	20.39	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$105.00	43.48%	0.00%	30.73	88.55	288.14%	24.86%
MCK McKesson Corporation	$897.16	31.93%	0.38%	19.60	-26.88	-137.16%	1.29%
VRTX Vertex Pharmaceuticals Incorporated	$542.40	39.41%	0.00%	31.57	6.87	21.76%	35.00%
CAH Cardinal Health Inc.	$235.19	59.60%	0.88%	35.20	-20.39	-57.93%	0.62%
HRMY Harmony Biosciences Holdings Inc.	$39.29	3.26%	0.00%	12.32	2.23	18.14%	18.89%
BIIB Biogen Inc.	$217.24	59.31%	0.00%	38.68	1.71	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

KIN Historical Dividends

current DY: %

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Kindred Biosciences

Kindred Biosciences Inc.

Average Investor10 user rating

4.0 (0 people)

United States

14 years

Founded: 2012

2013

Time since IPO - 13 years

63

Employees

Kindred Biosciences Inc. (United States) is listed on the Nasdaq and has a market capitalization of $-, with shareholders equity totaling $79.77 million.

The company employs approximately 63 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Kindred Biosciences Inc. reported $7.93 million in revenue, generating net income of $-41.95 million.

Key financial metrics include a P/E ratio of -, a price-to-book (P/B) ratio of -, and a trailing twelve-month dividend yield of -.

The company trades under the ticker KIN.

Market cap

Net worth

$79.77 million

$79,769,000.00

Assets

$108.87 million

$108,872,000.00

Total Shares Outstanding

45.28 million

45,277,000

Average Daily Trading Volume

$1.00 million

$1,003,371.64

Sector

Health Care

Industry

Biotechnology

KIN

KIN revenue and profits

Financial Results KIN

DRAG THE FRAME TO SEE MORE DATA

KIN cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$897.16 31,33% (12M)

P/E

19.60

0.38%

ROE

-137.16%

P/BV

-26.88

CAH - Cardinal Health

$235.19 60,10% (12M)

P/E

35.20

0.88%

ROE

-57.93%

P/BV

-20.39

JNJ - Johnson & Johnson

$266.50 54,96% (12M)

P/E

31.09

1.93%

ROE

24.76%

P/BV

7.70

ABBV - AbbVie

$256.91 26,00% (12M)

P/E

74.16

2.58%

ROE

-106.44%

P/BV

-78.93

MRK - Merck & Co.

$147.77 82,50% (12M)

P/E

116.78

2.24%

ROE

7.55%

P/BV

8.81

AZN - AstraZeneca

$161.98 3,46% (12M)

P/E

24.59

1.93%

ROE

20.74%

P/BV

5.10

PFE - Pfizer

$27.87 22,54% (12M)

P/E

35.86

6.26%

ROE

5.11%

P/BV

1.83

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$897.16 31,33% (12 M)

P/L

19.60

0.38%

ROE

-137.16%

P/VP

-26.88

CAH - Cardinal Health

$235.19 60,10% (12 M)

P/L

35.20

0.88%

ROE

-57.93%

P/VP

-20.39

JNJ - Johnson & Johnson

$266.50 54,96% (12 M)

P/L

31.09

1.93%

ROE

24.76%

P/VP

7.70

ABBV - AbbVie

$256.91 26,00% (12 M)

P/L

74.16

2.58%

ROE

-106.44%

P/VP

-78.93

MRK - Merck & Co.

$147.77 82,50% (12 M)

P/L

116.78

2.24%

ROE

7.55%

P/VP

8.81

AZN - AstraZeneca

$161.98 3,46% (12 M)

P/L

24.59

1.93%

ROE

20.74%

P/VP

5.10

PFE - Pfizer

$27.87 22,54% (12 M)

P/L

35.86

6.26%

ROE

5.11%

P/VP

1.83

Frequently Asked Questions

What is the price of Kindred Biosciences (KIN) today?

A cotação de Kindred Biosciences (KIN) hoje está em US$ 0.00, com uma variação de 0% em relação ao último ano. A cotação de Kindred Biosciences (KIN) iniciou o ano negociando na casa dos US$ 0.00 e hoje está em US$ 0.00. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Kindred Biosciences (KIN) e dados de ações do Ibovespa e mercados internacionais.

Quando Kindred Biosciences (KIN) paga dividendos?

Kindred Biosciences (KIN) não distribuiu dividendos no último ano.

Is Kindred Biosciences (KIN) a good investment?

Atualmente, Kindred Biosciences (KIN) está cotada a US$ 0.00, com um P/L de 0.00, representando um desvio de 0% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 0 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de -%. O retorno total do acionista foi de 0.00%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Kindred Biosciences (KIN) stock?

Investir em ações de Kindred Biosciences (KIN) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Kindred Biosciences (KIN) yield today?

A rentabilidade de Kindred Biosciences (KIN) foi de 0.00% no último mês, 0.00% no último ano e 0.00% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de -%.

Se você quisesse comprar 100 ações de Kindred Biosciences (KIN) hoje, o investimento total seria de US$ 0.00, com base na cotação atual de US$ 0.00.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 0.00
Em 5 anos: US$ 0.00
Em 10 anos: US$ 0.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

KIN

Kindred Biosciences Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment KIN

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING KIN WITH OTHER STOCK

current DY: %

5-year average DY: 0.00%

ABOUT Kindred Biosciences

Kindred Biosciences Inc.

United States

14 years

2013

63

Financial Results KIN

KIN cash flow

Asset, Revenue and Profit Growth - KIN

KIN balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions